Ryan Luke Sodemann

Ryan Luke Sodemann

Auto-generated profile, based on publicly available information

Ryan Luke Sodemann

Department of Neurosurgery, Massachusetts General Hospital , Boston, MA 02114 , USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
Neha KapateNeha Kapate
Neha Kapate
RLRick Liao
Rick Liao
RSRyan Luke Sodemann
Ryan Luke Sodemann
TSTawny Stinson
Tawny Stinson
SPSupriya Prakash
Supriya Prakash
SMSamir Mitragotri
Samir Mitragotri
Traumatic brain injury (TBI) is a debilitating disease with no current therapies outside of acute clinical management. While acute, controlled inflammation is important for debris clearance and regeneration after injury, chronic, rampant inflammation plays a significant adverse role in the pathophysiology of secondary brain injury. Immune cell therapies hold unique therapeutic potential for inflammation modulation, due to their active sensing and migration abilities. Macrophages are particularly suited for this task, given the role of macrophages and microglia in the dysregulated inflammatory response after TBI. However, maintaining adoptively transferred macrophages in an anti-inflammatory, wound-healing phenotype against the proinflammatory TBI milieu is essential. To achieve this, we developed discoidal microparticles, termed backpacks, encapsulating anti-inflammatory interleukin-4, and dexamethasone for ex vivo macrophage attachment. Backpacks durably adhered to the surface of macrophages without internalization and maintained an anti-inflammatory phenotype of the carrier macrophage through 7 days in vitro. Backpack–macrophage therapy was scaled up and safely infused into piglets in a cortical impact TBI model. Backpack–macrophages migrated to the brain lesion site and reduced proinflammatory activation of microglia in the lesion penumbra of the rostral gyrus of the cortex and decreased serum concentrations of proinflammatory biomarkers. These immunomodulatory effects elicited a 56% decrease in lesion volume. The results reported here demonstrate, to the best of our knowledge, a potential use of a cell therapy intervention for a large animal model of TBI and highlight the potential of macrophage-based therapy. Further investigation is required to elucidate the neuroprotection mechanisms associated with anti-inflammatory macrophage therapy.

30 January 2026 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
ETEmma Tinney
Emma Tinney
MNMark C. Nwakamma
Mark C. Nwakamma
GEGoretti España-Irla
Goretti España-Irla
MPMadeleine Perko
Madeleine Perko
RSRyan Luke Sodemann
Ryan Luke Sodemann
TMTimothy P. Morris
Timothy P. Morris
Mild traumatic brain injury (mTBI) is a prevalent neurological condition, affecting millions worldwide, and frequently resulting in persistent cognitive impairment that significantly impacts daily functioning. Current clinical management and recommendations lack evidence based therapeutic interventions, with treatment approaches limited to symptom monitoring and activity modification. Non-pharmaceutical interventions are needed to promote cognitive recovery and mitigate long-term consequences of mTBI. The goal of this randomized control pilot study is to evaluate the feasibility and preliminary efficacy of a symptom-guided and virtually delivered aerobic exercise intervention for improving cognitive function following mTBI. We are conducting a 12-week pilot randomized control trial of exercise to promote recovery from mTBI, which aims to recruit 24 participants who have suffered an mTBI within the last year and are between the ages of 18–55 years old. Participants are randomly assigned to one of two groups: an intervention group receiving 90 min of virtually-delivered, symptom-guided aerobic exercise weekly for 12 weeks, or a control group receiving 90 min of virtually-delivered balance exercises weekly for 12 weeks. Comprehensive assessments, including cognitive testing and multimodal neuroimaging, were conducted pre and post intervention. We implement physical activity monitoring during weeks 1, 6, and 12 using accelerometry to measure behavior changes. This study will establish the feasibility of virtual exercise delivery in mTBI populations and preliminary evidence regarding cognitive and brain health benefits of aerobic exercise in mTBI. Results will inform future large-scale trials and contribute to an accessible, evidence-based intervention for cognitive recovery after mTBI.

16 October 2026 in Restorative Neurology and Neuroscience
Verified
Journal Article
Open access
MNMark C Nwakamma
Mark C Nwakamma
ETEmma Tinney
Emma Tinney
MPMadeleine Perko
Madeleine Perko
GEGoretti España-Irla
Goretti España-Irla
LKLauren Kong
Lauren Kong
TMTimothy P Morris
Timothy P Morris
Mild traumatic brain injury (mTBI) often creates a sequela of symptoms that complicate safely participating in aerobic exercise. Although exertional assessments have been used to evaluate exercise tolerance, data on the feasibility of using test-derived metrics to guide the intensity of aerobic exercise interventions in community-dwelling adults is yet to be presented. This secondary analysis of a wider pilot randomized control trial examined whether a modified exertional bike test (MEBT) could be used to effectively individualize supervised virtual aerobic exercise without exacerbating symptoms in individuals with a mTBI. Adults (18–55 years) diagnosed of mTBI within the previous 12 months completed the MEBT and were randomized to either a 12-week supervised virtual aerobic exercise intervention or active balance control. Those randomized to the aerobic group exercised at 65–80% of HR at MEBT-derived symptom threshold or volitional exhaustion. Descriptive session outcomes, Spearman correlations, and Fisher's z tests assessed (1) the feasibility of symptom-threshold HR intervention metrics, (2) changes in the HR–symptom relationship over time, and (3) the influence of mTBI-related confounders on HR-symptom associations. Participants completed 95.6% of aerobic sessions, with symptom exacerbation (≥3-unit increase) reported in just 3.8% of sessions. Ten of 12 participants displayed a decreased, or negative, HR–symptom severity association over time. In addition, Fisher's z tests revealed confounding variables did not meaningfully modify the HR-symptom association. Sub-symptom-thresholded exercise sessions limited symptom exacerbation, uncoupled the HR–symptom relationship, and improved exercise tolerance over time. These findings highlight the feasibility of exertional symptom-guided virtual aerobic exercise following mTBI and support progression towards larger efficacy trials.